Portuguese 
English 
Spanish 
3 min of reading 
0 comments 
Promising Advance in Movement Recovery
Brazilian researchers announced the creation of polylaminin, a synthetic protein inspired by components of the human placenta.
The substance has been in experimental phases since 2024 and has shown encouraging results in patients with spinal cord injuries.
The Federal University of Rio de Janeiro (UFRJ) observed some results even in cases considered irreversible.
National Scientific Discovery
The team led by researcher Tatiana Coelho de Sampaio from UFRJ developed polylaminin.
The compound acts directly on neuron regeneration by forming a biological mesh capable of reconnecting axons.
With this action, axons restore the transmission of nerve impulses in patients with spinal cord injuries.
Patients who faced paralysis began to feel, move, and in some cases, even walk again.
In 2024, emblematic cases such as that of Bruno Drummond showed significant recovery.
Doctors diagnosed tetraplegia after the accident, but he began to walk again with the aid of a walker.
Results in Humans and Animals
Between 2024 and 2025, initial clinical trials involved eight Brazilian patients.
Of these patients, six showed relevant progress, such as gains in sensitivity and motor control.
Athlete Hawanna Cruz, also tetraplegic, reported significant improvement in trunk control after treatment with the new protein.
In parallel studies with animals, the results were also surprising.
Four out of six paraplegic dogs treated with the substance were able to take steps again after weeks of follow-up.
These data reinforce the transformative potential of polylaminin.
-
Miners in South Africa are extracting gold at a depth of 4,220 meters where the rock reaches 66°C and 5,400 tons are extracted per day.
-
TSMC unveils in the Arizona desert the $165 billion Fab 21 chip factory that will produce 100 million processors for Apple.
-
China conducts an unprecedented experiment with artificial embryos in space to discover how life reacts to the lack of gravity and cosmic radiation.
-
Largest iceberg in the world shrinks from 1,182 km² to 170 km² in three months after nearly four decades adrift in the South Atlantic
Experimental Phase and Next Steps
Despite the observed progress, polylaminin is still under evaluation by the scientific community.
It depends on the approval of the National Health Surveillance Agency (Anvisa) for large-scale clinical use.
Later this year, new studies will be conducted at renowned institutions, such as the Hospital das Clínicas of USP and Santa Casa de São Paulo.
The focus will be on patients who suffered acute injuries up to four days after the trauma.
This stage will be essential to consolidate the safety and efficacy of the treatment.
Future Perspectives for Treatment
If efficacy is confirmed, polylaminin may be integrated into the Unified Health System (SUS). In addition, it may become an accessible and innovative alternative in the treatment of spinal cord injuries.
As a consequence, this discovery could transform the reality of thousands of Brazilians facing motor limitations. For many, it means more than just a scientific advance.
Thus, the result paves the way for resuming movement, gaining autonomy, and restoring quality of life. Therefore, the expectations regarding the treatment are growing throughout the country.
Moreover, the research reinforces that when science and innovation come together, new medical achievements become possible. Thus, polylaminin symbolizes hope and real change for Brazilian patients.
Be the first to react!